Codice QR

Evaluation of the Clinical Outcomes of Apixaban Use in Patients with Atrial Fibrillation and Uncontrolled Hypothyroidism: A Real-world Evidence

Introduction Atrial fibrillation (AF) poses a substantial worldwide health concern, significantly increasing the risk of stroke and morbidity. Direct oral anticoagulants (DOACs) such as apixaban are recommended over vitamin K antagonists for the management of AF. However, the impact of thyroid abnor...

Descrizione completa

Salvato in:
Autori principali: Khalid Al Sulaiman BCCCP, BCNSP, MBA, FCCM, Manal A Aljohani PharmD, Abdullah F Alharthi PharmD, Hisham A Badreldin PharmD, Mohammed Y Alzahrani PharmD, Rahaf A Alqahtani PharmD, Walaa A Alshahrani PharmD, Fatimah M Abudayah PhD, Mohammad S Shawaqfeh PharmD, PhD, Ahmed A Alrashed PharmD, Alaa M Alenazi PharmD, Nouf S Alsagri PharmD, Mohammed Yahya Asiri PharmD, Zayed Asiri PharmD, Sulaiman Aljarallah PharmD, Yusuf M. Garwan PharmD, Lama S. Alfehaid PharmD, Abeer A. Alenazi PharmD, Tariq Aldebasi MD, Shmeylan Alharbi PharmD, Ahmed Aldemerdash PharmD, Amer Alzahrani MD, Ohoud Aljuhani PharmD
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publishing 2025-09-01
Serie:Clinical and Applied Thrombosis/Hemostasis
Accesso online:https://doi.org/10.1177/10760296251371043
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi